Triple-Drug attack shows promise for tough liver cancers
NCT ID NCT07157306
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests a combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) as a second treatment for people with advanced liver cancer that got worse after initial immunotherapy. The goal is to see if this new mix can shrink tumors or slow the cancer safely. About 35 adults whose cancer cannot be removed by surgery and who are expected to live at least 3 months will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.